2016, Number S1
<< Back Next >>
Rev Mex Anest 2016; 39 (S1)
Cannabinoids in chronic pain. An alternative or a risk?
Monroy-Álvarez CJ, Garduño-López AL, Gaspar-Carrillo SP, Nuche-Cabrera E, Ayón-Villanueva H
Language: Spanish
References: 11
Page: 11-13
PDF size: 139.29 Kb.
Text Extraction
No abstract.
REFERENCES
Mills B, Yepes A, Nugent K. Synthetic cannabinoids. Am J Med Sci. 2015;350:59-62.
Maldonado R, Baños JE, Cabañero D. The endocannabinoid system and neuropathic pain. Pain. 2016;157 Suppl 1:S23-S32.
Nadal X, La Porta C, Andreea Bura S, Maldonado R. Involvement of the opioid and cannabinoid systems in pain control: new insights from knockout studies. Eur J Pharmacol. 2013;716:142-157.
Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA. 1990;87:1932-1936.
Lee MC, Ploner M, Wiech K, Bingel U, Wanigasekera V, Brooks J, et al. Amygdala activity contributes to the dissociative effect of cannabis on pain perception. Pain. 2013;154:124-134.
Rom S, Persidsky Y. Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation. J Neuroimmune Pharmacol. 2013;8:608-620.
Wang T, Collet JP, Shapiro S, Ware MA. Adverse effects of medical cannabinoids: a systematic review. CMAJ. 2008;178:1669-1678.
Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain. 2010;150:573-581.
Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015;313:2456-2473.
Ware MA, Desroches J. Medical cannabis and pain. Pain. 2014;22:1-7.
Murineddu G, Deligia F, Dore A, Pinna G, Asproni B, Pinna GA. Different classes of CB2 ligands potentially useful in the treatment of pain. Recent Pat CNS Drug Discov. 2013;8:42-69.
Full text